Ep. 256, Chapter 2: The Investment Landscape Of Psychedelic Drug Development With Srinivas Rao

9:33 – 13:29

Dr. Srinivas Rao discusses the shifting investment landscape for psychedelic therapies. Momentum started to build following the 2019 approval of Spravato®, a form of ketamine used to treat depression. The COVID-19 pandemic brought a surge of biotech investments, fueling rapid growth in the psychedelic space, but that enthusiasm dwindled in late 2021 amid broader biotech downturns. Despite the challenges — regulatory obstacles, market volatility, and a cautious investor pool — promising assets can still attract funding.